Immunotherapies targeting CD38 in Multiple Myeloma

Recently, the monoclonal antibody daratumumab was approved as a single agent for the treatment of patients with relapsed/refractory Multiple Myeloma (MM). Daratumumab is an antibody targeting surface molecule CD38 on myeloma cells and the agent is already widely being used based on its good tolerabi...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Oncoimmunology
Prif Awduron: Atanackovic, Djordje, Steinbach, Mary, Radhakrishnan, Sabarinath Venniyil, Luetkens, Tim
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Taylor & Francis 2016
Pynciau:
Review
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5139636/
https://ncbi.nlm.nih.gov/pubmed/27999737
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2016.1217374
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg